Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) Net Margin (2018 - 2025)

Historic Net Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 333.47%.

  • Regenerative Medical Technology's Net Margin fell 2436500.0% to 333.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 131.77%, marking a year-over-year increase of 764800.0%. This contributed to the annual value of 135.37% for FY2024, which is 1636700.0% up from last year.
  • Latest data reveals that Regenerative Medical Technology reported Net Margin of 333.47% as of Q3 2025, which was down 2436500.0% from 132.73% recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Net Margin ranged from a high of 12.13% in Q4 2022 and a low of 10630.36% during Q1 2021
  • Moreover, its 5-year median value for Net Margin was 132.73% (2025), whereas its average is 1236.34%.
  • Data for Regenerative Medical Technology's Net Margin shows a peak YoY increase of 1051950900bps (in 2021) and a maximum YoY decrease of -60657500bps (in 2021) over the last 5 years.
  • Over the past 5 years, Regenerative Medical Technology's Net Margin (Quarter) stood at 617.97% in 2021, then skyrocketed by 102bps to 12.13% in 2022, then tumbled by -2469bps to 287.25% in 2023, then surged by 85bps to 42.3% in 2024, then plummeted by -688bps to 333.47% in 2025.
  • Its Net Margin was 333.47% in Q3 2025, compared to 132.73% in Q2 2025 and 55.62% in Q1 2025.